Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by Str8Shuteron Apr 17, 2020 6:19pm
169 Views
Post# 30924079

RE:160 Recovered Patients Test Positive Again

RE:160 Recovered Patients Test Positive AgainYes indeed.  One can imagine that if the antibodies that remain in people who have developed immunity against COVID-19 only last a few months, as is the case with the more common human coronaviruses, then widespread and repeated antibody testing may be required in order to limit the risk of repeated COVID-19 outbreaks in our workplaces. 

If we want to keep the economy going once it has been gradually ramped up again, then I would think that this could bode well for companies who can provide reliable serology testing to the masses.

Any company that can also offer reliable "proprietary molecular diagnostic tests for early detection of diseases and personalized health management, with a primary focus on cancer-related indications", leveraging the same convenient Telehealth platform, should be rather well positioned for significant growth.

The next NR should be interesting!


PeerReviewed wrote: Troubling and complicating things, if re-infection becomes the norm!

And to sort things out, no doubt it's gonna take tests. 
Lots of tests.



More than 160 South Koreans have tested positive a second time for the coronavirus, a development that suggests the disease may have a longer shelf life than expected.




Bullboard Posts